Carfilzomib reverses pulmonary arterial hypertension.

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Cardiovascular Research

• Publication date

  2016-05-15

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1093/cvr/cvw047PMID 26952044PMCID PMC4836627
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Mechanism of the Susceptibility of Remodeled Pulmonary Vessels to Drug‐Induced Cell Killing

  2014influential reference
• Carfilzomib.

  2013cited by this paper
• Mito-Tempol and Dexrazoxane Exhibit Cardioprotective and Chemotherapeutic Effects through Specific Protein Oxidation and Autophagy in a Syngeneic Breast Tumor Preclinical Model

  2013cited by this paper
• Adenosine monophosphate-activated protein kinase is required for pulmonary artery smooth muscle cell survival and the development of hypoxic pulmonary hypertension.

  2013cited by this paper
• U.S. Food and Drug Administration Approval: Carfilzomib for the Treatment of Multiple Myeloma

  2013cited by this paper
• The role of antioxidants in the era of cardio-oncology

  2013cited by this paper
• Severe pulmonary arterial hypertension induced by SU5416 and ovalbumin immunization.

  2012influential reference
• Modern age pathology of pulmonary arterial hypertension.

  2012cited by this paper
• TP53INP1, a tumor suppressor, interacts with LC3 and ATG8-family proteins through the LC3-interacting region (LIR) and promotes autophagy-dependent cell death

  2012cited by this paper
• Bortezomib alleviates experimental pulmonary arterial hypertension.

  2012influential reference
• Inhibition of ubiquitin proteasome function suppresses proliferation of pulmonary artery smooth muscle cells

  2011cited by this paper
• Analysis of the Lung Allocation Score Estimation of Risk of Death in Patients With Pulmonary Arterial Hypertension Using Data From the REVEAL Registry

  2010cited by this paper
• Survival in incident and prevalent cohorts of patients with pulmonary arterial hypertension

  2010cited by this paper
• Formation of Plexiform Lesions in Experimental Severe Pulmonary Arterial Hypertension

  2010cited by this paper
• Survival in pulmonary arterial hypertension: a reappraisal of the NIH risk stratification equation

  2009cited by this paper
• The Structure of Rat Liver Vault at 3.5 Angstrom Resolution

  2009cited by this paper
• AMP-activated Protein Kinase Inhibits Transforming Growth Factor-β-induced Smad3-dependent Transcription and Myofibroblast Transdifferentiation*

  2008cited by this paper
• Autophagy in the pathogenesis of disease.

  2008cited by this paper
• Host Resistance to Lung Infection Mediated by Major Vault Protein in Epithelial Cells

  2007cited by this paper
• p53-induced inhibition of Hif-1 causes cardiac dysfunction during pressure overload

  2007cited by this paper
• Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome.

  2007cited by this paper
• Pulmonary arterial hypertension: current therapeutic strategies

  2007cited by this paper
• Regulation of Bcl-xL expression in lung vascular smooth muscle.

  2007cited by this paper
• An evidence-based approach to the management of pulmonary arterial hypertension.

  2006cited by this paper
• Cellular functions of vaults and their involvement in multidrug resistance.

  2006cited by this paper
• An evidence-based approach to the management of pulmonary arterial hypertension.

  2006cited by this paper
• Adenosine Monophosphate-Activated Protein Kinase Suppresses Vascular Smooth Muscle Cell Proliferation Through the Inhibition of Cell Cycle Progression

  2005cited by this paper
• Cellular and molecular pathobiology of pulmonary arterial hypertension.

  2004cited by this paper
• AMP-Activated Protein Kinase Inhibits Angiotensin II– Stimulated Vascular Smooth Muscle Cell Proliferation

  2004cited by this paper
• Velcade: U.S. FDA approval for the treatment of multiple myeloma progressing on prior therapy.

  2003cited by this paper
• Apoptosis meets proteasome, an invaluable therapeutic target of anticancer drugs.

  2003cited by this paper
• Doxorubicin Induces Apoptosis and CD95 Gene Expression in Human Primary Endothelial Cells through a p53-dependent Mechanism*

  2002cited by this paper
• Inhibition of the VEGF receptor 2 combined with chronic hypoxia causes cell death‐dependent pulmonary endothelial cell proliferation and severe pulmonary hypertension

  2001cited by this paper
• The use of serum levels of cardiac troponin T to compare the protective activity of dexrazoxane against doxorubicin- and mitoxantrone-induced cardiotoxicity

  2001cited by this paper
• A chemical inhibitor of p53 that protects mice from the side effects of cancer therapy.

  1999cited by this paper
• Survival in patients with primary pulmonary hypertension. Results from a national prospective registry.

  1991cited by this paper

• Cancer Therapy-Related Pulmonary Hypertension: Implicated Agents, Diagnostic Considerations, and Management Strategies

  2026cites this paper
• Drugs and toxins associated with pulmonary arterial hypertension: from established culprits to novel threats

  2025cites this paper
• Detection and Evaluation of Drug-associated Pulmonary Arterial Hypertension.

  2025cites this paper
• Integrating pharmacogenetics, multi‐omics and machine learning in the novel therapeutic view of pulmonary hypertension

  2025cites this paper
• Cancer Drug Bortezomib, a Proteasomal Inhibitor, Triggers Cytotoxicity in Microvascular Endothelial Cells via Multi-Organelle Stress

  2025cites this paper
• Proteasome inhibitor bortezomib prevents proliferation and migration of pulmonary arterial smooth muscle cells

  2024cites this paper
• Understanding the molecular regulatory mechanisms of autophagy in lung disease pathogenesis

  2024cites this paper
• Canagliflozin differentially modulates carfilzomib-induced endoplasmic reticulum stress in multiple myeloma and endothelial cells

  2024cites this paper
• Exploring the pathogenesis of pulmonary vascular disease

  2024cites this paper
• Cancer Therapy-Associated Pulmonary Hypertension and Right Ventricular Dysfunction: Etiologies and Prognostic Implications

  2024cites this paper
• Cancer Therapy-Related Pulmonary Hypertension: A Review of Mechanisms and Implications for Clinical Practice

  2023cites this paper
• Transcriptional profiles of pulmonary artery endothelial cells in pulmonary hypertension

  2023cites this paper
• The emerging landscape of non-conventional RNA functions in atherosclerosis.

  2023cites this paper
• Cardiovascular Toxicity of Proteasome Inhibitors in Multiple Myeloma Therapy.

  2022cites this paper
• Attenuating effect of magnesium on pulmonary arterial calcification in rodent models of pulmonary hypertension

  2022cites this paper
• P53: Stability from the Ubiquitin–Proteasome System and Specific 26S Proteasome Inhibitors

  2022cites this paper
• Carfilzomib-induced pulmonary hypertension with associated right ventricular dysfunction: A case report

  2021cites this paper
• COVID-19 patients may become predisposed to pulmonary arterial hypertension

  2021cites this paper
• Drug and Solute Transporters in Mediating Resistance to Novel Therapeutics in Multiple Myeloma.

  2021cites this paper
• Bortezomib Inhibits Hypoxia-Induced Proliferation by Suppressing Caveolin-1/SOCE/[Ca2+]i Signaling Axis in Human PASMCs

  2021cites this paper
• Oxygen sensing, mitochondrial biology and experimental therapeutics for pulmonary hypertension and cancer.

  2021cites this paper
• Exploration of the Shared Gene Signatures and Molecular Mechanisms Between Systemic Lupus Erythematosus and Pulmonary Arterial Hypertension: Evidence From Transcriptome Data

  2021cites this paper
• Investigating the Vascular Toxicity Outcomes of the Irreversible Proteasome Inhibitor Carfilzomib

  2020cites this paper
• Strategies to Treat Pulmonary Hypertension Using Programmed Cell Death-Inducing Anti-Cancer Drugs without Damaging the Heart

  2020cites this paper
• Evidence for the role of cell reprogramming in naturally occurring cardiac repair

  2020cites this paper
• Myocardial proteomic profile in pulmonary arterial hypertension

  2020cites this paper
• Hepatic Failure From Pennyroyal Tea Interaction With Medications Metabolized by the Cytochrome P450 Enzymes.

  2020cites this paper
• Drug Development Targeting the Ubiquitin–Proteasome System (UPS) for the Treatment of Human Cancers

  2020cites this paper
• Autophagy and pulmonary disease

  2019cites this paper
• Molecular mechanisms of carfilzomib-induced cardiotoxicity in mice and the emerging cardioprotective role of metformin.

  2019cites this paper
• Ultrastructural Changes of the Right Ventricular Myocytes in Pulmonary Arterial Hypertension

  2019cites this paper
• Altered proteasome function in right ventricular hypertrophy.

  2019cites this paper
• Overexpression of p53 due to excess protein O-GlcNAcylation is associated with coronary microvascular disease in type 2 diabetes.

  2019cites this paper
• Effects of 6-mercaptopurine in pressure overload induced right heart failure

  2019cites this paper
• Carfilzomib-Induced Pulmonary Hypertension.

  2019cites this paper
• Drug-Induced Pulmonary Arterial Hypertension: Mechanisms and Clinical Management

  2019cites this paper
• Drug-associated pulmonary arterial hypertension

  2018cites this paper
• Mitochondrial HSP90 Accumulation Promotes Vascular Remodeling in Pulmonary Arterial Hypertension

  2018cites this paper
• The cardioprotective effect of dexrazoxane (Cardioxane) is consistent with sequestration of poly(ADP-ribose) by self-assembly and not depletion of topoisomerase 2B

  2018cites this paper
• Cardiovascular adverse events in multiple myeloma patients.

  2018cites this paper
• New heights and hot topics in Cardiovascular Research

  2018cites this paper
• Autophagy and its role in pulmonary hypertension

  2018cites this paper
• Effects of Bcl-2/Bcl-xL Inhibitors on Pulmonary Artery Smooth Muscle Cells

  2018influential citation
• Insights on the epigenetic mechanisms underlying pulmonary arterial hypertension

  2018cites this paper
• The role of autophagy in pulmonary hypertension: a double-edge sword

  2018cites this paper
• Hypoxia-induced alterations in the lung ubiquitin proteasome system during pulmonary hypertension pathogenesis

  2018cites this paper
• New drugs, therapeutic strategies, and future direction for the treatment of Pulmonary Arterial Hypertension.

  2018cites this paper
• The cancer theory of pulmonary arterial hypertension

  2017cites this paper
• Pulmonary Hypertension and Cancer: Etiology, Diagnosis, and Management

  2017cites this paper
• Docetaxel Reverses Pulmonary Vascular Remodeling by Decreasing Autophagy and Resolves Right Ventricular Fibrosis

  2017influential citation
• Vitamin E Nicotinate

  2017cites this paper
• Molecular Mechanisms of the Cardiotoxicity of the Proteasomal-Targeted Drugs Bortezomib and Carfilzomib

  2017cites this paper
• Semaphorin-3E attenuates neointimal formation via suppressing VSMCs migration and proliferation

  2017cites this paper
• Apoptosis-based therapy to treat pulmonary arterial hypertension

  2016cites this paper
• Inhibition of MLCK attenuates pulmonary artery hypertension

  2016cites this paper
• Second-generation proteasome inhibitor carfilzomib sensitizes neuroblastoma cells to doxorubicin-induced apoptosis

  2016cites this paper
• Major vault protein in cardiac and smooth muscle

  2016cites this paper